Clinical Trial Search

Primary: Activity of SJ733 Administered Orally on Clearance of P. Falciparum Blood Stage Parasites From the Blood in Healthy Subjects (Men and WNCBP) — 172; 11551 Parasite…

Primary: Treatment-related Adverse Events (TEAE) Reporting of RJX — 2; 1; 2; 0 Participants

Primary: Safety and Tolerability as Measured by Adverse Events — 0; 0; 0; 0 participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Number of Participants With Adverse Events — 2; 2; 2; 1 participants

Primary: Incidence of Drug-related Adverse Events [Safety and Tolerability] — 2; 2; 1; 0 participants

Primary: 7-day Point Prevalence of Smoking Abstinence — 4; 0 Participants

Primary: Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization). — 0 Participants

Primary: Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84) — 7.108; 7.083; 0.333; 1.000 hours

Primary: Pharmacokinetic Parameters of MCI-186: Peak Drug Concentration (Cmax) — 347.6; 280.3 ng/mL

Primary: Summary of Derived Best Tumor Response Per the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 - Dose Escalation (Efficacy Evaluable Population) — 0…

Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF — 250.4 Hours*nanogram per…

Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 5; 5; 10 Participants

Primary: Change in Clinician Administered PTSD Scale (CAPS) — -20.67 units on a scale

Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) — 6; 40; 9; 7 milligrams (mg)